RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

被引：0
|
作者：
Moura, Filipe [1 ]
Berg, David [1 ]
Bellavia, Andrea [1 ]
Mosenzon, Ofri [1 ]
Dwyer, Jamie [1 ]
Scirica, Benjamin M. [1 ]
Wiviott, Stephen [1 ]
Bhatt, Deepak L. [1 ]
Raz, Itamar [1 ]
Feinberg, Mark William [1 ]
Morrow, David A. [1 ]
Sabatine, Marc Steven [1 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 81卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1493-176
引用
收藏
页码：1808 / 1808
页数：1
相关论文
共 50 条
  • [1] Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
    Moura, Filipe A.
    Berg, David D.
    Bellavia, Andrea
    Dwyer, Jamie P.
    Mosenzon, Ofri
    Scirica, Benjamin M.
    Wiviott, Stephen D.
    Bhatt, Deepak L.
    Raz, Itamar
    Feinberg, Mark W.
    Braunwald, Eugene
    Morrow, David A.
    Sabatine, Marc S.
    DIABETES CARE, 2023, 46 (10) : 1807 - 1815
  • [2] The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
    Kobayashi, Kazuo
    Toyoda, Masao
    Hatori, Nobuo
    Sakai, Hiroyuki
    Furuki, Takayuki
    Tamura, Kouichi
    Miyakawa, Masaaki
    DIABETES, 2019, 68
  • [3] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
    David C. Wheeler
    June James
    Dipesh Patel
    Adie Viljoen
    Amar Ali
    Marc Evans
    Kevin Fernando
    Debbie Hicks
    Nicola Milne
    Philip Newland-Jones
    John Wilding
    Diabetes Therapy, 2020, 11 : 2757 - 2774
  • [4] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
    Wheeler, David C.
    James, June
    Patel, Dipesh
    Viljoen, Adie
    Ali, Amar
    Evans, Marc
    Fernando, Kevin
    Hicks, Debbie
    Milne, Nicola
    Newland-Jones, Philip
    Wilding, John
    DIABETES THERAPY, 2020, 11 (12) : 2757 - 2774
  • [5] Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (03) : 243 - 256
  • [6] Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
    Kelly, Michael S.
    Lewis, Jelena
    Huntsberry, Ashley M.
    Dea, Lauren
    Portillo, Ivan
    POSTGRADUATE MEDICINE, 2019, 131 (01) : 31 - 42
  • [7] SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (12) : 1879 - 1904
  • [8] The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
    Weir, Matthew R.
    POSTGRADUATE MEDICINE, 2016, 128 (03) : 290 - 298
  • [9] SGLT2 Inhibition, Visceral Adiposity, Weight, and Type 2 Diabetes Mellitus
    Carbone, Salvatore
    O'Keefe, James H.
    Lavie, Carl J.
    OBESITY, 2020, 28 (07) : 1173 - 1173
  • [10] Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
    Pfister, M.
    Whaley, J. M.
    Zhang, L.
    List, J. F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (04) : 621 - 625
12345